TY - JOUR

T1 - Viroporiners potentiale som lægemiddeltargets med fokus på SARS-CoV-2

AU - Sund, John D

AU - Bollerup, Signe

AU - Glamann, Jekob B

AU - Vinten, Caroline An

AU - Jensen, Louise R

AU - Toft-Bertelsen, Trine L

AU - Bentzen, Bo H

AU - Kledal, Thomas N

AU - Weis, Nina

AU - Rosenkilde, Mette

PY - 2022/6/13

Y1 - 2022/6/13

N2 - Viroporins are ion channels found in many viruses, where they contribute to virus life cycle and thereby pathogenesis. Viroporin targeting is a known, yet largely unexplored, therapeutic strategy so far only used in Influenza A with the drugs amantadine and rimantadine. In this review, we seek to utilize the inhibition by amantadine of the viroporin Protein E in SARS-CoV-2 in an attempt to treat COVID-19 in its early stages. We are executing a double-blinded placebo-controlled trial based on promising in vivo and in vitro work as a stepping-stone for establishing a therapeutic antiviral regime: blocking of viroporins.

AB - Viroporins are ion channels found in many viruses, where they contribute to virus life cycle and thereby pathogenesis. Viroporin targeting is a known, yet largely unexplored, therapeutic strategy so far only used in Influenza A with the drugs amantadine and rimantadine. In this review, we seek to utilize the inhibition by amantadine of the viroporin Protein E in SARS-CoV-2 in an attempt to treat COVID-19 in its early stages. We are executing a double-blinded placebo-controlled trial based on promising in vivo and in vitro work as a stepping-stone for establishing a therapeutic antiviral regime: blocking of viroporins.

KW - Amantadine

KW - Antiviral Agents/pharmacology

KW - COVID-19/drug therapy

KW - Humans

KW - SARS-CoV-2

KW - Viroporin Proteins

M3 - Review

C2 - 35703076

VL - 184

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 24

M1 - V02220103

ER -